CandlesenseCandlesense
DGX•benzinga•

Quest Diagnostics Reaffirmed 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.769B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.71)

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 19, 2025 by benzinga

← Back to DGX News
    Quest Diagnostics Reaffirmed 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.769B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.71) | DGX Stock News | Candlesense